Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541423 | 0.99 | EGFR (0.42) | EGFRERBB2JAK3ERBB4KDR | |
| SCHEMBL14213727 | 0.84 | PIP4K2A (0.51) | EGFRERBB2JAK3ERBB4PIP4K2A | |
| SCHEMBL13541425 | 0.84 | PIP4K2A (0.52) | EGFRERBB2JAK3ERBB4PIP4K2A | |
| SCHEMBL16158633 | 0.83 | PIP4K2A (0.46) | EGFRERBB2JAK3TNNI3KPIP4K2A | |
| SCHEMBL12262381 | 0.83 | EGFR (0.57) | EGFRERBB2JAK3ERBB4KDR | |
| SCHEMBL14213729 | 0.81 | MET (0.39) | EGFRERBB2JAK3ERBB4PIP4K2A | |
| SCHEMBL14213726 | 0.81 | EGFR (0.36) | EGFRERBB2JAK3ERBB4PIP4K2A | |
| SCHEMBL13542519 | 0.81 | EGFR (0.39) | EGFRERBB2JAK3ERBB4KDR | |
| SCHEMBL13541421 | 0.81 | MET (0.40) | EGFRERBB2JAK3ERBB4PIP4K2A | |
| SCHEMBL13541424 | 0.81 | JAK3 (0.36) | EGFRERBB2JAK3ERBB4PIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329901-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB2 918/4885JAK3 439/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB2 918/4885JAK3 439/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB2 918/4885JAK3 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.